|
A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium Clinical research trials and A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium. A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium clinical trial. Human subjects often obtain the finest healthcare possible for their A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium  A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium
A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium
For Condition: Urologic Neoplasms
Status: Recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body. - You must have at least one tumor that can be physically measured or scanned by x-ray. - You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago. Exclusion Criteria: - You may not have used an experimental medicine or device within the past month. - Cancer that has spread to your brain. - If you are unwilling or unable to take folic acid or vitamin B12 supplements.
Total Enrollment:
Location and Contact Information:
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." *Recruiting*
Pikonlinna, ,
Finland
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." *Recruiting*
Paris Cedex 14, ,
France
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." *Recruiting*
Montpellier, ,
France
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." *Recruiting*
Marseille Cedex 09, ,
France
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." *Recruiting*
Turku, ,
Finland
Recruiting
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
HOMBURG / SAAR, ,
Germany
Recruiting
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Lille Cedex, ,
France
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." *Recruiting*
Helsinki, ,
Finland
Recruiting
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician." *Recruiting*
Bordeaux Cedex, ,
France
Recruiting
Additional Information:
Study ID Numbers: 4699;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034593
Other Urologic Neoplasms Studies:
1. A Phase 2 Trial of ALIMTA (pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
2. Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples
3. A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium
4. Safety and Efficacy of S-8184 in Second Line Treatment of Locally Advanced, Metastatic, or Recurrent Transitional Cell Carcinoma of the Urothelium
Related Studies:
Other Urologic Neoplasms Clinical Trials
Other Clinical Trials
Other Lille Cedex Clinical Trials
A Phase 2 Trial of ALIMTA (pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional cell Carcinoma of the Urothelium
|
|
|
|
|
|
|
|
